Cohort Study: Taking 5-ARIs for BPH is not associated with increased mortality in prostate cancer.

News Release: Taking 5-ARIs for BPH is not associated with increased mortality in prostate cancer – Karolinska Institute

Original Study: Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality – JAMA Oncology (link to abstract – $ for full-text)

Authors Interview: Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality – JAMA

Commentary: Large study finds no increased risk for prostate cancer death with 5-ARI use – medwire News

Commentary on Twitter

This large population-based cohort study found that men treated with 5α-reductase inhibitors had no increased risk of dying from #prostatecancer, on the contrary indicating a decreased risk with longer treatment duration. https://t.co/y8HlpthNI9 #PCSM #GUCSM

— JAMA Oncology (@JAMAOnc) May 19, 2022